While these are general guidelines, the precise dosage of each tends to vary with therapeutic context
For patients who cannot tolerate statins or require additional lipid lowering despite maximum tolerated statin therapy, NICE guidance supports several alternative or adjunctive treatments: Ezetimibe : Reduces cholesterol absorption from the intestine and can be used alone or in combination with statins PCSK9 inhibitors (evolocumab, alirocumab): Injectable medications reserved for specific high-risk patients with familial hypercholesterolaemia or established cardiovascular disease who have not achieved targets with other therapies Bempedoic acid : A newer oral option for patients with statin intolerance Inclisiran : An injectable treatment given twice yearly for primary hypercholesterolaemia or mixed dyslipidaemia in line with NICE criteria Icosapent ethyl : For people with established cardiovascular disease and raised triglycerides despite statin therapy Fibrates : Primarily used for severe hypertriglyceridaemia Lifestyle modifications remain fundamental to cholesterol management and should be implemented alongside any pharmacological treatment
Riley DR, Essa H, Austin P, et al
Our lead clinical personality, Susan Jones, an RN, APRN, MSN, FNP with NPI 1639347107, has seen firsthand how this innovative treatment can transform lives, helping patients regain control and achieve a healthier future
Our study is observational and these results should therefore be replicated in a randomised controlled trial to confirm and extend our findings, said Dr Max Taquet, Clinical Lecturer at the University of Oxford and senior author of the study
